New York, May 04, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Bladder Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030” – https://www.reportlinker.com/p06067935/?utm_source=GNW
98 billion in 2020 to $1.14 billion in 2021 at a compound annual growth rate (CAGR) of 16.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.26 billion in 2025 at a CAGR of 18.7%.
The bladder cancer drugs market consists of sales of bladder cancer drugs.Bladder cancer is cancerous tissue that occurs on the lining of the bladder.
These cancerous tissues are also called tumors and have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments of bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others.
In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion.The transaction helps Bristol-Myers acquire a bigger market share of immuno-oncology drugs including bladder cancer drugs in the USA and compete with its competitors.
Celgene corporation, a company that…